Advanced Lung Cancer, Lung Cancer, Metastatic Lung Cancer, Non-Small Cell Lung Cancer, NSCLC, SCLC, Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Stage IV Lung Cancer
Conditions
Keywords
FGFR1 amplification, FGF alteration, VEGF alteration, PDGF alteration, Tyrosine kinase inhibitor, VEGFR inhibitor, FGFR inhibitor, PDGFR inhibitor, VEGFR-FGFR inhibitor
Brief summary
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with advanced/metastatic lung cancer and fibroblast growth factor (FGF), vascular endothelial growth factor receptor (VEGF), or platelet derived growth factor (PDGF) related genetic alterations.
Detailed description
Lucitanib is an oral inhibitor of the tyrosine kinase activity of FGFR 1-3, VEGFR 1-3, and PDGFR α/β. Lucitanib has demonstrated potent anti-tumor and anti-angiogenic activity in vitro proliferation assays and in vivo using human tumor xenograft models, with a trend for stronger efficacy in those with genomic aberrancies of FGF or PDGF. Abnormalities in the FGF, VEGF, and PDGF-related genes are observed across lung cancer histologies. The first in human trial of lucitanib demonstrated that daily lucitanib is clinically active in patients with advanced solid tumors. Specifically, patients with FGFR1-amplification appeared to derive particular benefit from lucitanib. Based on these results, this study is designed to explore the safety and anti-tumor activity of daily lucitanib in lung cancer patients with FGF, VEGF, and PDGF genetic alterations.
Interventions
DRUGLucitanib
Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity. Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability.
Sponsors
Clovis Oncology, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC * Any of the following tumor tissue based genetic alterations: FGFR1, FGFR2, FGFR3, VEGFA, or PDGFRα amplification; Any FGFR1, FGFR2, or FGFR3 gene fusion; FGFR1, FGFR2, or FGFR3 activating mutation * Availability of tumor tissue sample suitable for the central confirmation of the genetic alteration and exploratory analyses * Eastern Cooperative Oncology Group (ECOG) of 0 or 1 * Measurable disease per RECIST 1.1 * Documented radiographic disease progression following at least one line of therapy in the advanced/metastatic setting
Exclusion criteria
* Tumors that are invading a major vessel; NSCLC tumors abutting to a major vessel * Uncontrolled hypertension, defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with optimized anti-hypertensive therapy * Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher than 5 mIU/mL while receiving appropriate thyroid hormone therapy * Symptomatic and/or untreated central nervous system metastases * Presence of another active cancer * Ongoing adverse events from surgery or prior anti-cancer therapies, including radiation, targeted, or cytotoxic therapies * Pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Screening, every 8 weeks; up to 2 years | Proportion of patients in whom a confirmed Complete Response (CR) or a confirmed Partial Response (PR), as best overall response according to RECIST criteria, is observed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | Screening, every 8 weeks; up to 2 years | Time from the date of first drug intake until the date of progression or death for any cause |
| Duration of response (DOR) | Screening, every 8 weeks; up to 2 years | For responders (i.e. patients with best overall response CR or PR), the interval from the time of first documentation of response to the date of progression or death for any cause |
| Duration of clinical benefit | Screening, every 8 weeks; up to 2 years | For responders and patients with SD as best overall response, time from the first drug intake until the date of progression or death for any cause |
| Overall Survival (OS) | Continuously; up to 2 years | From the date of first drug intake to the date of death for any cause |
| Clinical Benefit Rate (CBR) | Screening, every 8 weeks; up to 2 years | Proportion of patients in whom a confirmed CR or confirmed PR or a prolonged Stable Disease (SD) (≥ 6 months), as best overall response according to RECIST, is observed |
| Incidence of adverse events (AEs), clinical laboratory abnormalities, and dose modifications | Continuously; up to 2 years | — |
| PK parameters of lucitanib | Cycle 1 Day 14 and 28, Cycle 2 Day 28, Cycle 3 Day 28 | — |
| Pharmacogenomic analysis of inter-patients variation in gene encoding ADME involved proteins | Cycle 1 Day 1 | — |
| Pharmacodynamic (PD) evaluation of lucitanib profile | Cycle 1 Day 1 and 14, End of Study | Soluble growth factors and other biomarkers, including circulating tumor DNA |
| Tumor growth kinetics | Screening, every 8 weeks; up to 2 years | Will be evaluated using the following criteria: tumor size; tumor volume; tumor growth |
Countries
France, Germany, Italy, Spain, United States
Outcome results
None listed